DRUGS & SUPPLEMENTS

Diflorasone

How old is patient?

Diflorasone uses

Indications and usage
Contraindications
Precautions
Adverse reactions
Overdosage
Dosage and administration
How supplied
Diflorasone reviews

INDICATIONS AND USAGE

Diflorasone cream USP, 0.05% is a high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

Diflorasone cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

General: Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.

Patients receiving a large dose of a higher potency topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH-stimulation, A.M. plasma cortisol, and urinary free-cortisol tests.

This product has a greater ability to produce adrenal suppression than does Diflorasone ointment, 0.05%. At 30 g per day (applied as 15 g twice daily) Diflorasone cream, 0.05% was shown to cause inhibition of the HPA axis in one of two patients following application for one week to psoriatic skin. At 15 g per day (applied as 7.5 g twice daily) Diflorasone cream was shown to cause mild inhibition of the HPA axis in one of five patients following application for one week to diseased skin (psoriasis or atopic dermatitis). These effects were reversible upon discontinuation of treatment. By comparison, Diflorasone ointment 0.05% did not produce significant HPA axis suppression when used in divided doses at 30 g per day for one week in patients with psoriasis or atopic dermatitis.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.

Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios (see PRECAUTIONS: Pediatric Use ).

If irritation develops, Diflorasone cream should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Diflorasone cream should be discontinued until the infection has been adequately controlled.

Diflorasone cream should not be used in the treatment of rosacea or perioral dermatitis, and it should not be used on the face, groin, or axillae.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

The medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
The medication should not be used for any disorder other than that for which it was prescribed.
The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive unless directed by the physician.
Patients should report to their physician any signs of local adverse reactions.

Laboratory Tests: The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH-stimulation test; A.M. plasma-cortisol test; Urinary free-cortisol test.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential of Diflorasone.

Diflorasone was not found to be mutagenic in a micronucleus test in rats at dosages of 2400 mg/kg.

Studies in the rat following topical administration at doses up to 0.5 mg/kg revealed no effects on fertility.

Pregnancy: Teratogenic effects–Pregnancy Category C. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application to laboratory animals.

Diflorasone has been shown to be teratogenic (cleft palate) in rats when applied topically at a dose of approximately 0.001 mg/kg/day to the shaven thorax of pregnant animals. This is approximately 0.3 times the human topical dose of Diflorasone cream. When pregnant rats were treated topically with approximately 0.5 mg/kg/day, uterine deaths were higher in the treated animals than in control animals.

In rabbits, cleft palate was seen when Diflorasone was applied in topical doses as low as 20 mg/kg/day. In addition, fetal weight was depressed and litter sizes were smaller.

There are no adequate and well-controlled studies of the teratogenic potential of Diflorasone in pregnant women. Diflorasone cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Diflorasone cream is administered to a nursing woman.

Pediatric Use: Safety and effectiveness of Diflorasone cream in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA-axis suppression when they are treated with topical corticosteroids. They are, therefore, also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and pediatric patients.

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

ADVERSE REACTIONS

The following local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, and miliaria.

OVERDOSAGE

Topically applied Diflorasone cream, can be absorbed in sufficient amounts to produce systemic effects.

DOSAGE AND ADMINISTRATION

Diflorasone Cream USP, 0.05% should be applied to the affected area twice daily.

HOW SUPPLIED

Diflorasone Cream USP, 0.05% is available as follows:

NDC 0168-0242-15 15 gram tube

NDC 0168-0242-30 30 gram tube

NDC 0168-0242-60 60 gram tube

Store at or below 25°C (77°F). Keep tightly closed.

E. FOUGERA & CO.

a division of Fougera Pharmaceuticals Inc.

Melville, New York 11747

I242B

R03/12

#171

NDC 0168-0242-15

Fougera^®

Diflorasone

CREAM USP, 0.05%

FOR EXTERNAL USE ONLY

NOT FOR OPHTHALMIC USE

Rx only

Each gram contains: 0.5 mg

Diflorasone in a cream base

consisting of cetyl alcohol, glyceryl

stearate SE (nonionic), isopropyl

myristate, mineral oil (and) lanolin,

alcohol, monobasic sodium phosphate,

monoglyceride citrate, polyoxyl 40

stearate, polysorbate 60, propylene

glycol, purified water, sorbitan

monostearate, vegetable oil, butylated

hydroxytoluene and citric acid.

NET WT 15 grams

NDC 0168-0242-15

Fougera^® Rx only

Diflorasone

CREAM USP, 0.05%

FOR EXTERNAL USE ONLY

NOT FOR OPHTHALMIC USE

WARNING: Keep out of reach

of children.

NET WT 15 grams

Diflorasone pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.

Diflorasone Diacetate

Diflorasone available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.

	Price
Cream; Topical; 0.05%
Diflorasone 0.05% cream	1.5 USD
Diflorasone Diacetate 0.05% Cream 15 gm Tube	38.25 USD
Diflorasone Diacetate 0.05% Cream 30 gm Tube	52.81 USD
Diflorasone Diacetate 0.05% Cream 60 gm Tube	101.11 USD
Diflorasone Diacetate 0.05% Ointment 15 gm Tube	38.05 USD
Diflorasone Diacetate 0.05% Ointment 30 gm Tube	52.29 USD
Diflorasone Diacetate 0.05% Ointment 60 gm Tube	100.5 USD
Ointment; Topical; 0.05%
Psorcon 0.05% Cream 60 gm Tube	137.58 USD
Psorcon 0.05% Ointment 60 gm Tube	145.75 USD
Psorcon 0.05% cream	3.45 USD

Diflorasone destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.

Human:
Topical corticosteroids

Diflorasone Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.

D07AC10 - Diflorasone

Diflorasone pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.

References

Dailymed."DIFLORASONE DIACETATE CREAM [E. FOUGERA & CO., A DIVISION OF FOUGERA PHARMACEUTICALS INC.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
"diflorasone". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
"diflorasone". http://www.drugbank.ca/drugs/DB0022... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Diflorasone?

Depending on the reaction of the Diflorasone after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Diflorasone not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Diflorasone addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

sdrugs.com conducted a study on Diflorasone, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Diflorasone consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.